BUZZ-Clearmind rises after advancing trial of alcohol-use disorder drug
Reuters03-11
BUZZ-Clearmind rises after advancing trial of alcohol-use disorder drug
** Shares of biotech company Clearmind MedicineCMND.O rise 10% to $1.10 premarket
** Co says it has begun enrolling participants in the third stage of its ongoing study for CMND‑100, an experimental drug for alcohol use disorder
** The condition is marked by difficulty controlling drinking despite harmful consequences; CMND‑100 aims to reduce cravings without causing hallucinations - CMND
** Co says move follows earlier studies showing the drug was safe and well‑tolerated
** Adds study sites include Yale University, Johns Hopkins University and Tel Aviv Sourasky Medical Center
** Shares fell ~97% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments